We are a clinical‑stage biotechnology company built upon a passion for innovation and a desire to challenge the established treatment options for patients with neurodegenerative diseases. We strive to deliver much‑needed therapies to patients with debilitating and life‑threatening neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease.
We aim to surpass currently available treatments.
RECENT PRESS RELEASES
14 May 2018
AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE® PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson’s Disease Patients.
27 August 2018
A specific active immunotherapy (SAIT) to control cholesterol levels in blood.
16 September 2018
Potential new advances against Huntington’s disease.
WHERE TO MEET US
12–14 March 2019
17th Annual Eyeforpharma Conference 2019
25 March 2019
Redefining Early Stage Investments (RESI)
25–27 March 2019
13th Annual International Partnering Conference, Bio-Europe Spring 2019
Specific Active ImmunoTherapy (SAIT)
Adherence to current therapies can be poor due to complex dosing regimens, and the treatment of many neurodegenerative diseases is still failing. Using our unique AFFITOME technology, we are developing Specific Active ImmunoTherapy (SAIT), which stimulates the body to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT induces a long‑lasting target-specific immune response, which may translate into effective quarterly or perhaps twice-yearly dosing.
SAIT is an exciting prospect.
We focus on identifying proteins that are involved in the development and progression of neurodegenerative diseases, and establishing novel SAIT treatments against pathogenic forms of these proteins using our unique AFFITOME technology. SAIT has successfully demonstrated proof of concept in both preclinical and clinical studies. Our most advanced product candidates are entering Phase II clinical trials.
We are moving forward.
”It is enormously gratifying to work in a team with a modality that could make such an impact on the future of neurodegenerative disease management. I get up every morning feeling that it really matters what we do.Oliver SiegelCEO